Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (200)	8/21/2001 2:52:29 AM
From: nigel bates	Respond to of 625

MELBOURN, England, Aug. 21 /PRNewswire/ -- Cambridge Antibody Technology (Nasdaq: CATG; LSE: CAT) today confirmed that the Judge in the district court of Washington DC has ruled on a number of matters in relation to the Griffiths patent (US 5,885,793). The Court was asked to rule on various matters of law after the jury was unable to reach a decision in April, other than finding that CAT was entitled to the priority dates of its British applications. On MorphoSys' invalidity assertions, the Judge found for CAT on four of MorphoSys' invalidity assertions and did not rule on the fifth. This last invalidity assertion will need to be tried in court. Whilst the Court has issued no ruling on infringement of the patent by MorphoSys, the judge indicated that he presently takes the view it appears that MorphoSys should prevail on this issue, principally because of the way the MorphoSys library is ``derived.'' However he acknowledges that ``it is not clear that CAT has been fully heard on the issue'' and thus has made no formal ruling. The Court will now instigate other proceedings and/or briefings which will allow CAT to argue the infringement issue before the court can come to a ruling on this matter. Dr. David Chiswell, CEO at CAT, said, ``We welcome the Court's rulings generally in favour of the validity of the Griffiths patent and we will continue to present our view to the Judge that MorphoSys do indeed infringe the patent. In addition to the Griffiths patent CAT is asserting the Winter II and the McCafferty patent families over MorphoSys in court actions in Europe and the USA. None of these cases will have any effect on CAT's freedom to operate and CAT believes that taking the actions as a whole, CAT will ultimately prevail.'' ...